Glucotrack公司新任质量副总裁Vincent Wong - Vincent Wong在生命科学和医疗器械制造领域拥有丰富经验，擅长建立质量管理功能，管理FDA检查，推动产品和流程风险管理活动[2] - Vincent Wong将负责建立和实施公司的质量体系和相关流程，包括风险管理、产品和流程验证、设计转移以及商业生产的可持续性[3] - Glucotrack公司CEO表示Vincent Wong的经验将对公司转向人体临床试验和商业化CBGM产品的过程产生巨大影响[4]

Glucotrack与Cirtec Medical Corp合作 - Glucotrack公司宣布与Cirtec Medical Corp签订了开发协议，选择后者作为其可植入式连续血糖监测仪(CBGM)的制造商[1] - CBGM是一种长期可植入系统，能持续测量血糖水平，传感器寿命超过2年，无需佩戴在身体上，只需进行一次校准[2] - Cirtec Medical是一家在植入式医疗设备领域领先的设计和制造公司，与Glucotrack合作将加速CBGM技术的临床试验和商业化进程[3]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 001-41141 GLUCOTRACK, INC. (Exact name of registrant as specified in its charter) Delaware 98 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 001-41141 GLUCOTRACK, INC. (Exact name of registrant as specified in its charter) Delaware 98-0668 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 001-41141 GLUCOTRACK, INC. (Exact name of registrant as specified in its charter) Delaware 98-066 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________________ to _________________________ Commission file number 000-54785 GLUCOTRACK, INC. (Exact name of registrant as specified in its charter) Delawa ...